AU Patent

AU2025202015A1 — Pharmaceutical compositions comprising meloxicam

Assigned to Axsome Therapeutics Inc · Expires 2025-04-10 · 1y expired

What this patent protects

The present invention relates to a method of treating migraine, comprising administering a dosage form comprising a meloxicam, at least 400 mg of a bicarbonate, and a rizatriptan to a human being suffering from migraine; wherein the human being has a history of inadequate respo…

USPTO Abstract

The present invention relates to a method of treating migraine, comprising administering a dosage form comprising a meloxicam, at least 400 mg of a bicarbonate, and a rizatriptan to a human being suffering from migraine; wherein the human being has a history of inadequate response to prior migraine treatments.

Drugs covered by this patent

Patent Metadata

Patent number
AU2025202015A1
Jurisdiction
AU
Classification
Expires
2025-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Axsome Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.